Fibroblasts: Key Mediators of Regeneration, Inflammation and Fibrosis (Volume II)

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 111

Special Issue Editor

1. Department of Rheumatology and Clinical Immunology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany
2. German Rheumatism Research Centre (DRFZ) Berlin, a Leibniz Institute, 10117 Berlin, Germany
Interests: cellular energy metabolism of immune cells; cellular glucocorticoid mechanisms and the role of HIF’s in cellular immune response and regeneration processes such as wound and fracture healing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Fibroblasts are spindle-shaped, site-specific cells of mesenchymal origin in the interstitial spaces of organs and part of the connective tissue. They include synovial fibroblasts, dermal fibroblasts, and bone marrow stromal cells. Fibroblasts are the primary source of interstitial extracellular matrix (ECM) proteins, mainly including collagen fibers, which, together with the proteoglycans that are also formed, provide increased strength for the extracellular matrix, forming a scaffold for cells. In addition to providing a scaffold for cells, ECM proteins play key roles in determining cell phenotype and function. Alongside ECM proteins, fibroblasts secrete proteolytic enzymes, growth factors, cytokines, and chemokines. Finally, fibroblasts adhere to and contract connective tissue and are capable of transdifferentiating into activated proliferative fibroblasts or myofibroblasts. Thus, it is not surprising that they are key players in acute and chronic inflammatory processes such as wound healing and fibrosis, cirrhosis dermatitis, and arthritis. In physiological ECM maintenance, the fibroblast repair program is self-limiting. By contrast, pathological fibrosis is characterized by uncontrolled fibroblast activation that results in exaggerated and persistent ECM accumulation and remodeling. The responses of fibroblasts to activation include proliferation, fibrinogenesis, and the release of cytokine and proteolytic enzymes. Fibroblasts are critical components of the granulation tissue of healing wounds or broken bones during soft callus formation. In the healing wound, the number of fibroblasts increases, while the number of inflammatory cells decreases. Increased numbers of fibroblasts or myofibroblasts occur primarily due to the local proliferation of local fibroblasts or other cells of mesenchymal origin such as pericytes, liver perisinusoidal cells, kidney mesangial cells, and epithelial cells after epithelial–mesenchymal transition. Myofibroblasts can also develop from circulating precursors such as mononuclear cells and circulating fibrocytes. Peripheral blood fibrocytes rapidly enter the site of injury at the same time as circulating inflammatory cells. Although they are important players in the process of wound healing, fibroblasts are involved in regulating many chronic inflammatory diseases such as rheumatoid arthritis, primary biliary cirrhosis, atherosclerosis, kidney interstitial fibrosis, and peritoneal fibrosis. This Special Issue will focus on fibroblasts and their critical role in a variety of diseases. In particular, for this Special Issue, contributions dealing with the characterization of fibroblasts, their mechanistic and metabolic switches from tissue-resident fibroblasts to proliferative myofibroblasts, fibrometabolism, the homing of fibrocytes to sites of inflammation, model systems of fibrosis, and therapeutic interference to prevent or treat fibrosis are highly encouraged.

Dr. Timo Gaber
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop